{Reference Type}: Journal Article
{Title}: N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer.
{Author}: Wen YR;Lin XW;Zhou YW;Xu L;Zhang JL;Chen CY;He J;
{Journal}: World J Gastrointest Oncol
{Volume}: 16
{Issue}: 3
{Year}: 2024 Mar 15
暂无{DOI}: 10.4251/wjgo.v16.i3.659
{Abstract}: <B>BACKGROUND: </B>Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival rate of less than 10%, owing to its late-stage diagnosis. Early detection of pancreatic cancer (PC) can significantly increase survival rates.<BR><B>OBJECTIVE: </B>To identify the serum biomarker signatures associated with early-stage PDAC by serum N-glycan analysis.<BR><B>METHODS: </B>An extensive patient cohort was used to determine a biomarker signature, including patients with PDAC that was well-defined at an early stage (stages I and II). The biomarker signature was derived from a case-control study using a case-cohort design consisting of 29 patients with stage I, 22 with stage II, 4 with stage III, 16 with stage IV PDAC, and 88 controls. We used multiparametric analysis to identify early-stage PDAC N-glycan signatures and developed an N-glycan signature-based diagnosis model called the "Glyco-model".<BR><B>RESULTS: </B>The biomarker signature was created to discriminate samples derived from patients with PC from those of controls, with a receiver operating characteristic area under the curve of 0.86. In addition, the biomarker signature combined with cancer antigen 19-9 could discriminate patients with PDAC from controls, with a receiver operating characteristic area under the curve of 0.919. Glyco-model demonstrated favorable diagnostic performance in all stages of PC. The diagnostic sensitivity for stage I PDAC was 89.66%.<BR><B>CONCLUSIONS: </B>In a prospective validation study, this serum biomarker signature may offer a viable method for detecting early-stage PDAC.